Cargando…
Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia
Imatinib mesylate (IM), a targeted competitive inhibitor of the BCR-ABL tyrosine kinase, has revolutionized the clinical treatment of chronic myeloid leukemia (CML). However, resistance and intolerance are still a challenge in the treatment of CML. Autophagy has been proposed to play a role in IM re...
Autores principales: | Shao, Shan, Li, Su, Qin, Youwen, Wang, Xiaorui, Yang, Yining, Bai, Haitao, Zhou, Lili, Zhao, Chuxian, Wang, Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904104/ https://www.ncbi.nlm.nih.gov/pubmed/24585095 http://dx.doi.org/10.3892/ijo.2014.2313 |
Ejemplares similares
-
The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR Through an Autophagy-Independent and USP13-Mediated Mechanism
por: Pesce, Emanuela, et al.
Publicado: (2018) -
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016) -
Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer
por: Liao, Yuning, et al.
Publicado: (2019) -
The autophagy inhibitor spautin-1, either alone or combined with doxorubicin, decreases cell survival and colony formation in canine appendicular osteosarcoma cells
por: Schott, Courtney R., et al.
Publicado: (2018) -
Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)